New patents for New week number 46 year 2017
10new patents,
Sr no
|
Patent number
|
name
|
company
|
INDICATION
|
REMARKS, WAIT FOR STR TO APPEAR
|
1
|
WO-2017197083
|
VOXELOTOR
|
GLOBAL BLOOD
|
Sickle cell anemia
| |
2
|
WO-2017196192
|
APREMILAST
|
ZAKLADY
| Behcets disease; Psoriasis; Psoriatic arthritis | |
3
|
|
OSATERONE
|
ZAKLADY
|
Osteoporosis; Prostate hyperplasia; Prostate tumor
| |
4
|
|
LEDIPASVIR
|
LUPIN
| Hepatitis C virus infection | |
5
|
|
ZOLEDRONIC ACID
|
GRUNENTHAL
|
Pagets bone disease
| |
6
|
WO-2017194002
|
BREXPIPRAZOLE
|
SHANGHAI
| Major depressive disorder; Schizophrenia | |
7
|
WO-2017193914
|
CRISABOROLE
|
SHANGHAI
| Atopic dermatitis; Psoriasis | |
8
|
WO-2017193913
|
FOSAPREPITANT
|
SHANGHAI
| Chemotherapy induced nausea and vomiting | |
9
|
WO-2017193662
|
TASIMELTEON
|
ZHEJIANG
|
Circadian rhythm sleep disorder
| |
10
|
WO-2017196859
|
ITRACONAZOLE
|
CHINESE UNIV
|
Fungal infection
| |
Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in totally blind adults. It is a selective agonist for the melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, Tasimelteon
ReplyDelete